PURPOSE IS TO PROVIDE A NO COST SCHEDULE EXTENSION AND EXTEND THE PERIOD OF PERFORMANCE FROM AUGUST 30, 2024 TO NOVEMBER 30, 2024. AS A RESULT ARTICLE(S) C.1., F.1. AND G.3. NEEDS TO BE UPDATED

LucidAct Inc. (LucidAct) is a Digital Health company that offers connected telemedicine and Remote Patient Monitoring (RPM) solutions specifically designed for patients that are non-tech savvy, living in rural areas, or having cultural and/or language barriers. We provide an end-to-end remote care management solution that combines connected medical devices, telehealth, and intelligent patient engagement into a single solution for healthcare organizations. LucidAct platform is cost effective, responsive, and user-friendly for all end-users, including patients, nurses, and physicians. Under this NCI contract, LucidAct will develop a digital tool for cancer prevention, in which we will identify patients that are at high-risk by assessing all potential risk factors including family history, genetics, and environmental factors (tobacco use, diet, obesity, etc.). We will offer science- and guideline-based recommendations to patients to engage in lifestyle changes to reduce cancer risk. LucidAct’s innovative workflow engine is customizable and configurable to manage complex care and to personalize recommendations to each individual patient. We have a team of healthcare and technology professionals that integrate expertise and healthcare data with PCP care and patient expectations to implement smart and usable solutions to complement and extend patient engagement beyond in-person visits. I-Corps supplement